Development of next generation of baculovirus vectors with tissue specific gene transduction
| Project/Area Number |
15K07926
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SAKAGUCHI Miako 長崎大学, 熱帯医学研究所, 助教 (50400651)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | バキュロウイルス / マラリア原虫 / バキュロウイルスベクター / マラリア |
|---|
| Outline of Final Research Achievements |
In this research, budded recombinant baculovirus vectors (BVs) have been developed because BVs have many advantages for tissue targeting gene delivery vectors.It is easily possible to display exogenous proteins on the surface of BV virion. CSP and TRAP, malaria sporozoite surface proteins have highly selective affinity to hepatocytes. BVs expressing CSP or TRAP molecule on the virion surface have been constructed and they were shown to greatly increase transduction efficacy to human hepatoma cell line (HepG2 et al.) and human primary hepatocytes (PXB cells). Furthermore, to overcome the vulnerability to serum complement system, fusion molecules of complement regulatory proteins were displayed to BV virion surfaces. These BVs were shown to greatly increase resistance against complement attack.
|
Report
(4 results)
Research Products
(6 results)
